Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
SAN FRANCISCO, Oct. 05, 2022 (GLOBE NEWSWIRE) -- Fountain Therapeutics (“Fountain”), a biopharmaceutical company leveraging proprietary breakthroughs in artificial intelligence and computational...
-
SAN FRANCISCO, Jan. 18, 2022 (GLOBE NEWSWIRE) -- Fountain Therapeutics (“Fountain”), a biopharmaceutical company leveraging a unique artificial intelligence platform driven by expertise in aging...
-
Brings total Series A financing to $26 million Funds to support expansion of leadership team, continued R&D activities and pre-clinical research SAN FRANCISCO, Nov. 18, 2021 (GLOBE NEWSWIRE)...
-
SOUTH SAN FRANCISCO, Calif., July 19, 2021 (GLOBE NEWSWIRE) -- Fountain Therapeutics, a biopharmaceutical company building a pipeline of therapeutics to treat age-related diseases by reversing...
-
SOUTH SAN FRANCISCO, Calif., April 26, 2021 (GLOBE NEWSWIRE) -- Fountain Therapeutics, a biopharmaceutical company building a pipeline of therapeutics to treat age-related diseases by reversing...
-
SAN FRANCISCO, Sept. 09, 2020 (GLOBE NEWSWIRE) -- Fountain Therapeutics (“Fountain”), a biopharmaceutical company building a pipeline of therapeutics to treat age-related diseases by reversing...
-
Closing brings total Series A financing sum to $11 million Funds to support expansion of team, technology platform and in vivo preclinical drug testing SAN FRANCISCO, May 19, 2020 (GLOBE...